Learn About Juvenile Myelomonocytic Leukemia (JMML)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Franco Locatelli practices in Rome, Italy. Mr. Locatelli is rated as an Elite expert by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Splenectomy.
Mignon Loh is a Pediatric Hematologist Oncology provider in San Francisco, California. Dr. Loh is rated as an Elite provider by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Bone Marrow Aspiration, and Bone Marrow Transplant.
Marco Zecca practices in Pavia, Italy. Mr. Zecca is rated as an Elite expert by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). His top areas of expertise are Juvenile Myelomonocytic Leukemia (JMML), Anemia, Aplastic Anemia, Bone Marrow Transplant, and Bone Graft.
Summary: This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop t...
Summary: This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.